Chemotherapy News and Research

Latest Chemotherapy News and Research

Arkansas professor makes strides toward developing enhanced cancer treatment

A University of Arkansas at Little Rock professor is making strides toward developing an effective cancer treatment without the severe side effects of traditional therapies.

13 Sep 2017

MTI awards $25,000 grant to MDI Biological Laboratory scientist for peripheral neuropathy research

The Maine Technology Institute has awarded a $25,000 seed grant to Sandra Rieger, Ph.D., of the MDI Biological Laboratory to study peripheral neuropathy, a condition that causes pain, tingling and numbness in the hands and feet and affects an estimated 20 to 40 million Americans.

13 Sep 2017

Study finds potential preventive for chemotherapy-induced peripheral neuropathy

Chemotherapy-induced peripheral neuropathy, or CIPN, is a common side effect of cancer treatment that causes shooting or burning pain, numbness, tingling and cold sensitivity of the hands and feet for many cancer patients.

13 Sep 2017

Researchers identify protein that offers likely target for treating high-risk pediatric cancers

Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy--harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells.

11 Sep 2017

Study: Chemoradiation should remain standard treatment for locally advanced cervical cancer

A 14-year randomised trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings are reported today at the ESMO 2017 Congress in Madrid. The trial demonstrated no improved disease-free survival with neoadjuvant chemotherapy followed by surgery.

11 Sep 2017

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Combination immunotherapy as second or third line treatment extends overall survival to at least 15 months in patients with pleural malignant mesothelioma, according to late-breaking results from the MAPS2 trial presented today at the ESMO 2017 Congress in Madrid.

11 Sep 2017

Study: Maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer

Rucaparib maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported today at the ESMO 2017 Congress in Madrid.

8 Sep 2017

Study: Immunotherapy shows promising response rate in patients with metastatic gastric cancer

Pembrolizumab has shown a promising response rate in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented today at the ESMO 2017 Congress in Madrid.

8 Sep 2017

Two new treatments may benefit patients with high risk prostate cancer, trial shows

Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid.

8 Sep 2017

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

The superiority of docetaxel based triplet therapy over standard care in patients with resectable oesophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.

8 Sep 2017

Comprehensive analysis reveals cumulative burden of chronic disease in childhood cancer survivors

The most complete assessment yet of chronic disease in adult survivors of childhood cancer found they have a nearly two-fold greater cumulative burden of chronic health problems than the general public.

8 Sep 2017

Differentiating sepsis and systemic inflammatory response syndrome using biomarkers

Firstly, it is necessary to make a distinction between systemic inflammation and Systemic Inflammatory Response Syndrome (SIRS). SIRS consists of changes in clinical signs including an abnormal body temperature, increased heart rate, increased respiratory rate, an abnormal white cell count (either decreased or elevated), or an increase in band neutrophils.

7 Sep 2017

New microfluidic device offers insights on cancer metastasis

As cancer grows, it evolves. Individual cells become more aggressive and break away to flow through the body and spread to distant areas.

7 Sep 2017

Study identifies genetic alterations with potential to promote aggressiveness of astrocytomas

Among the various types of cancerous brain tumors, 70% are astrocytomas. Fatal in as many as 90% of cases, astrocytomas originate in the largest and most numerous cells in the central nervous system, called astrocytes because of their star shape.

6 Sep 2017

Reduced dose of chemotherapy has no effect on overall survival of liver cancer patients

Patients with the most common type of liver cancer who are taking the chemotherapy drug sorafenib can begin their treatment with a lower dose than is currently considered standard, and it will not affect how long they live when compared to patients who start on the full dose.

6 Sep 2017

Scientist receives NIH grant to investigate tumor microenvironment from relatively new context

Cancer metastasis – the spread of disease from the original site to a distant organ – remains a major challenge in treating cancer and a main cause of morbidity and mortality.

6 Sep 2017

Prostate cancer screening reduces cancer deaths finds new analysis

There has been much debate regarding the utility of prostate cancer screening in reducing the rates of deaths due to this cancer among men. While the ERSPC (European Randomized Study of Screening for Prostate Cancer) suggests that screening reduced prostate cancer deaths, the PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) found that regular screening does not reduce the cancer death rates in prostate cancer. Researchers thus looked at the actual picture as to which of these – ERSPC or PLCO are correct.

5 Sep 2017

Chemotherapy News and Research

Latest Chemotherapy News and Research

Arkansas professor makes strides toward developing enhanced cancer treatment

MTI awards $25,000 grant to MDI Biological Laboratory scientist for peripheral neuropathy research

Study finds potential preventive for chemotherapy-induced peripheral neuropathy

Researchers identify protein that offers likely target for treating high-risk pediatric cancers

Study: Chemoradiation should remain standard treatment for locally advanced cervical cancer

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Study: Maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer

Study: Immunotherapy shows promising response rate in patients with metastatic gastric cancer

Two new treatments may benefit patients with high risk prostate cancer, trial shows

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

Comprehensive analysis reveals cumulative burden of chronic disease in childhood cancer survivors

Differentiating sepsis and systemic inflammatory response syndrome using biomarkers

New microfluidic device offers insights on cancer metastasis

Study identifies genetic alterations with potential to promote aggressiveness of astrocytomas

Reduced dose of chemotherapy has no effect on overall survival of liver cancer patients

Scientist receives NIH grant to investigate tumor microenvironment from relatively new context

Prostate cancer screening reduces cancer deaths finds new analysis

Another way for anti-vaxxers to skip shots for schoolkids: A doctor’s note

Zika virus may one day be effective treatment for deadly brain cancer

Increased genomic risk can make small tumors aggressive, study says

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in